Form 4: Vir Biotechnology CEO Marianne De Backer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Marianne De Backer, CEO of Vir Biotechnology, sold 72,995 shares of common stock on April 3, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On April 3, 2024, Marianne De Backer, the CEO of Vir Biotechnology, sold 72,995 shares of the company's common stock.
- The sale was executed at a price of $9.4577 per share.
- The transaction was conducted to cover the issuer's tax withholding and remittance obligations associated with the vesting of restricted stock units.
- Following the transaction, De Backer directly owns 678,457 shares of Vir Biotechnology.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.
Key Dates
| Date | Description |
|---|---|
| 04/03/2024 | Date of the stock sale transaction. |
| 04/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.